Astellas bets on Vir cancer drug, and other licensing deals Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

#pharmalicensingdeals #pharmaceuticalassets #VirBiotech #Vir #HarbourBioMed #UnnaturalProducts #Genhouse #CSL #Astellas #SolsticeOncology #antiCTLA4antibody #Novartis #UnnaturalProducts #macrocyclicpeptidedrugs #GileadSciences #syntheticlethality #GenhouseBio #Arcellx #EliLilly
zurl.co/HOdjt

🧬 New preprint out!
Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens.
🔗 doi.org/10.64898/202...
#PrecisionOncology #SyntheticLethality #FANCA #AURKA #CancerGenomics

A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.

If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.

pls share 🙏

Just back from the GRC on Synthetic Lethality in Oncology: great science, deep discussion, great venue and flawless organisation. Thanks to @mgarnett.bsky.social, Benjamin Schwartz & @vazquezf.bsky.social for leading a fantastic meeting at the frontier of cancer research #SyntheticLethality #GRC

Enjoying the Gordon Conference on Synthetic Lethality in Oncology with @francescoiorio.bsky.social and @maxbillmann.bsky.social 😊 #bioinformatics #gordonConference #syntheticLethality

Synthetic Lethality is redefining cancer treatment across the globe. With a CAGR of 14.6%, the global market is expanding fast, from USD 1.3B in 2024 to USD 3.87B by 2032.

👉 Access Full Report: www.credenceresearch.com/report/synth...

#AIinHealthcare #DrugDiscovery #SyntheticLethality

Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality

SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...

(1/3) Excited to share our latest work using
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!

We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO

#CancerResearch #SyntheticLethality #Genomics #DepMap

Synthetic lethal strategies for the development of cancer therapeutics - Nature Reviews Clinical Oncology The experience with PARP inhibitors provides evidence of the clinical utility of synthetic lethality, whereby the simultaneous presence of two specific alterations is required for antitumour activity....

Discover #syntheticLethality: using CRISPR-Cas9 tech to identify new therapeutic targets in cancer, tackling undruggable pathways. Breakthroughs in treatment loom. #cancer #innovation PMID:39627502, Nat Rev Clin Oncol 2024 doi.org/10.1038/s415...

Of the Blackman’s in science, this one has the best hair and best headshot. #SABCS2017 #syntheticlethality